1. Market Research
  2. > Pharmaceutical
  3. > Pathology Market Trends
  4. > EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast To 2022

EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast To 2022

Summary

Acute myeloid leukemia (AML) is a rare cancer that accounts for a disproportionally high number of cancer-related deaths (O’Donnell et al., 2012; RKI, 2012). The disease is more common in the elderly and is slightly more common in men than in women (ACS, 2013; O’Donnell et al., 2012). AML progresses quickly and has low survival and high rates of relapse even with treatment (ACS, 2013; ASCO, 2012; O’Donnell et al., 2012). The age of the patient, specifically over or under 60 years of age, and the classification of the disease are important factors that determine the treatment plan (NCI, 2013; Shah et al., 2013).

GlobalData epidemiologists forecast that the 6MM had 23,497 incident cases of AML in 2012, and close to half of the incident cases occurred in the US. The 6MM will experience an increase in disease burden driven by population increase in the next 10 years at the rate of 1.80% per year, resulting in 27,717 incident cases in 2022. The growth of incident cases in the US is the highest amongst all markets at 2.29% per year, whereas the 5EU (France, Germany, Italy, Spain, and the UK) has a slightly slower growth rate of 1.33% per year from 2012–2022.

Scope

- The acute myeloid leukemia (AML) EpiCast Report provides an overview of the risk factors and the global and historical epidemiological trends for AML in the six major markets (6MM): the US, France, Germany, Italy, Spain, and the UK. In addition, the report also includes a 10-year forecast of the following segmentations in adults aged 20 and older across the 6MM.
- Incident cases of AML segmented by sex and 10-year age groups
- Five-year prevalent cases of AML segmented by the age groups 20–59 years and ending at ages 60 years and older
- Incident and five-year prevalent cases of acute promyelocytic leukemia (APL) and myelodysplastic syndromes/therapy-related acute myeloid leukemia (MDS/therapy-related AML) segmented by the age groups 20–59 years and ending at ages 60 years and older
- Incident cases of AML with mutations in the FLT3 gene
- Incident cases of AML classified in favorable, intermediate, and adverse risk groups

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global AML market.
- Quantify patient populations in the global AML market to improve product development, pricing, and launch plans.
- Organize sales and marketing efforts by identifying sex, age groups, subtypes, and risk groups that present the best opportunities for AML therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast To 2022
Table of Contents

1 Table of CContents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.2.1 Increased age is associated with increased risk and worsened prognosis 12
3.2.2 Smoking increases risk of M2 AML 13
3.2.3 APL is more common among Spanish and Italian origins 14
3.2.4 Chemotherapy and radiation therapy increases risk of AML 14
3.2.5 Benzene increases risk of AML 15
3.3 Global Trends 16
3.3.1 Incidence 16
3.3.2 Survival and Prevalence 18
3.3.3 Subtypes and Mutations 19
3.3.4 Risk Groups 21
3.4 Forecast Methodology 24
3.4.1 Sources Used 25
3.4.2 Forecast Assumptions and Methods 31
3.4.3 Sources Not Used 36
3.5 Epidemiological Forecast of Acute Myeloid Leukemia (2012-2022) 36
3.5.1 Incident Cases of AML 36
3.5.2 Incident Cases of AML by Age 38
3.5.3 Incident Cases of AML by Sex 40
3.5.4 Age-Standardized Incidence of AML 42
3.5.5 Incident Cases of AML Subtypes 43
3.5.6 Incident Cases of AML Subtypes by Age 46
3.5.7 Incident Cases of AML with Mutations in the FLT3 Gene 48
3.5.8 Incident Cases of AML by Risk Group Classifications 49
3.5.9 Five-Year Prevalent Cases of AML 53
3.5.10 Five-Year Prevalent Cases of AML by Age 56
3.5.11 Five-Year Prevalent Cases of APL and MDS/Therapy-Related AML 57
3.5.12 Five-Year Prevalent Cases of APL and MDS/Therapy-Related AML by Age 59
3.6 Discussion 62
3.6.1 Epidemiological Forecast Insight 62
3.6.2 Limitations of the Analysis 62
3.6.3 Strengths of the Analysis 63
4 Appendix 64
4.1 Bibliography 64
4.2 About the Authors 71
4.2.1 Epidemiologists 71
4.2.2 Reviewers 71
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 73
4.2.4 Global Head of Healthcare 73
4.3 About GlobalData 74
4.4 About EpiCast 74
4.5 Disclaimer 75



List of Tables

Table 1: Risk Factors and Comorbidities for AML in Adults 12
Table 2: Estimated Frequencies of Cytogenetic Abnormalities in AML 22
Table 3: Risk Group Classification Guidelines 23
Table 4: 6MM, Sources of AML Incidence 24
Table 5: 6MM, Incident Cases of AML, Men and Women Aged ? 20 Years, N, Selected Years, 2012-2022 37
Table 6: 6MM, Incident Cases of AML by Age, Men and Women, N (row %), 2012 38
Table 7: 6MM, Incident Cases of AML by Sex, N (Row %), 2012 40
Table 8: 6MM, Incident Cases of APL, Men and Women Aged ? 20 Years, N (Column %), Selected Years, 2012-2022 43
Table 9: 6MM, Incident Cases of MDS/Therapy-related AML, Men and Women Aged ? 20 Years N (Column %), Selected Years 2012-2022 44
Table 10: 6MM, Incident Cases of AML Subtypes by Age, Men and Women, N (Row % in Each Subtype), 2012 46
Table 11: 6MM, Incident Cases of AML with FLT3 Mutations, Men and Women Aged ? 20, N (Column %), Selected Years 2012-2022 48
Table 12: 6MM, Risk Group Classification of AML Incident Cases, Men and Women Aged ? 20 Years, N (Row %), 2012 50
Table 13: US, Risk Group Classification of AML Incident Cases by Age, Men and Women, N (Row %), 2012 52
Table 14: 6MM, Five-Year Prevalent Cases of AML, Men and Women Aged ? 20 Years, N (Column %), Selected Years, 2012-2022 54
Table 15: 6MM, Five-Year Prevalent Cases of AML by Age, Men and Women, N (Row %), 2012 56
Table 16: 6MM, Five-Year Prevalent Cases of APL, Men and Women Aged ? 20 Years, N (Column %), Selected Years 2012-2022 57
Table 17: 6MM, Five-Year Prevalent Cases of MDS/Therapy-Related AML, Men and Women Aged ? 20 Years, N (Column %), Selected Years 2012-2022 58
Table 18: 6MM, Prevalent Cases of AML Subtypes by Age, Men and Women, N (Row % in Each Subtype), 2012 60



List of Figures

Figure 1: 6MM, Incident Cases of AML, Men and Women Aged ? 20 Years, N, 2012-2022 37
Figure 2: 6MM, Incident Cases of AML by Age, Men and Women Aged ? 20 Years, N, 2012 39
Figure 3: 6MM, Incident Cases of AML by Sex, Aged ? 20, N, 2012 41
Figure 4: 6MM, Age-Standardized Incidence of AML, Aged ? 20 Years, 2012 42
Figure 5: 6MM, Incident Cases of APL and MDS/Therapy-Related AML, Men and Women Aged ? 20, N, 2012 and 2022 45
Figure 6: 6MM, Incident Cases of AML Subtypes by Age, Men and Women, N, 2012 47
Figure 7: 6MM, Incident Cases of AML with FLT3 Mutations, Men and Women Aged ? 20, N, 2012-2022 49
Figure 8: 6MM, Risk Group Classification of AML Incident Cases, Men and Women Aged ? 20 Years, N, 2012 51
Figure 9: US, Risk Group Classification of AML Incident Cases by Age, Men and Women, N, 2012 52
Figure 10: 6MM, Five-Year Prevalent Cases of AML, Men and Women Aged ? 20 Years, N, 2012-2022 55
Figure 11: 6MM, Prevalent Cases of AML Subtypes by Age, Men and Women, N, 2012 61

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • April 2015
  • by Global Data

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023 Summary Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all ...

Breast Cancer: KOL Insight

Breast Cancer: KOL Insight

  • $ 7 495
  • Industry report
  • May 2015
  • by Firstword Pharma

How will breast cancer be treated in the years ahead – and what targeted therapies represent the greatest potential in terms of transforming disease therapy? KOL Insight: Breast Cancer provides a comprehensive ...

Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • June 2015
  • by GBI Research

Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation Summary Pancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality ...


Download Unlimited Documents from Trusted Public Sources

Oncology Industry in Europe

  • July 2015
    6 pages
  • Oncology  

    Chemotherapy  

    Cancer  

  • Europe  

    World  

    Switzerland  

View report >

Pathology Description in Canada

  • July 2015
    71 pages
  • Cancer  

    Therapy  

  • Canada  

View report >

Pathology Description in Europe and the US - Forecast

  • July 2015
    3 pages
  • Diabetes  

  • Europe  

    United States  

View report >

Sugar Markets

16 days ago

Related Market Segments :

Cancer

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.